Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens

Bone Marrow Transplantation

Volumn 28, Issue 5, 2001, Pages 455-461

  Gutierrez Delgado, F ^a   Maloney, D G ^a,b   Press, O W ^a,b   Golden, J ^a,b   Holmberg, L A ^a,b   Maziarz, R T ^a   Hooper, H ^a   Buckner, C D ^a,b   Appelbaum, F R ^a,b   Bensinger, W I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Busulfan; High dose chemotherapy; Lymphomas; Melphalan; Stem cell transplantation; Thiotepa

Indexed keywords

ACICLOVIR; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MILODISTIM; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; THIOTEPA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG TOXICITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; REMISSION; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0035175271     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703179     Document Type: Article

References (35)

1. Treatment of non-Hodgkin's lymphoma
2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
3. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle
4. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation
5. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma
6. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
7. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
8. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy
9. One hundred auto-transplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome
10. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers
11. Chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma
12. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma
13. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
14. Fifth report of EBMTG experience of ABMT in malignant lymphoma
15. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
16. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma
17. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells
18. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease
19. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer
20. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
22. Technique for human marrow grafting
23. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
24. The effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation
25. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement
26. Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation
27. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
28. Interleukin-2 ± lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies
29. Regimen-related toxicity in patients undergoing bone marrow transplantation
30. Critical care and respiratory failure
31. Gastrointestinal and hepatic complications
32. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
33. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
34. High-dose therapy and autografting for follicular low grade lymphoma in first temission: The Stanford experience
35. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma